To further evaluate the correlation between CFL1 expression and sorafenib sensitivity, we analyzed the survival benefit of HCC patients (n = 29) received standard sorafenib treatment in TCGA database. The gene discussed is CFL1; the disease is hepatocellular carcinoma.